» Articles » PMID: 22695412

Persistent Inflammation and Immunosuppression: a Common Syndrome and New Horizon for Surgical Intensive Care

Overview
Specialty Critical Care
Date 2012 Jun 15
PMID 22695412
Citations 359
Authors
Affiliations
Soon will be listed here.
Abstract

Surgical intensive care unit (ICU) stay of longer than 10 days is often described by the experienced intensivist as a "complicated clinical course" and is frequently attributed to persistent immune dysfunction. "Systemic inflammatory response syndrome" (SIRS) followed by "compensatory anti-inflammatory response syndrome" (CARS) is a conceptual framework to explain the immunologic trajectory that ICU patients with severe sepsis, trauma, or emergency surgery for abdominal infection often traverse, but the causes, mechanisms, and reasons for persistent immune dysfunction remain unexplained. Often involving multiple-organ failure (MOF) and death, improvements in surgical intensive care have altered its incidence, phenotype, and frequency and have increased the number of patients who survive initial sepsis or surgical events and progress to a persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Often observed, but rarely reversible, these patients may survive to transfer to a long-term care facility only to return to the ICU, but rarely to self-sufficiency. We propose that PICS is the dominant pathophysiology and phenotype that has replaced late MOF and prolongs surgical ICU stay, usually with poor outcome. This review details the evolving epidemiology of MOF, the clinical presentation of PICS, and our understanding of how persistent inflammation and immunosuppression define the pathobiology of prolonged intensive care. Therapy for PICS will involve innovative interventions for immune system rebalance and nutritional support to regain physical function and well-being.

Citing Articles

Prognostic impact of hypernatremia for septic shock patients in the intensive care unit.

Shi M, Chen J, Ji F, Zhou H, Peng K, Wang J World J Clin Cases. 2025; 13(7):95430.

PMID: 40051797 PMC: 11612684. DOI: 10.12998/wjcc.v13.i7.95430.


Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).

Xiong D, Geng H, Lv X, Wang S, Jia L J Inflamm Res. 2025; 18:2267-2281.

PMID: 39968098 PMC: 11834740. DOI: 10.2147/JIR.S504694.


Dynamic changes in peripheral blood lymphocyte trajectory predict the clinical outcomes of sepsis.

Li D, Zhang J, Cheng W, Zhao G, Lei X, Xie Y Front Immunol. 2025; 16:1431066.

PMID: 39967662 PMC: 11832464. DOI: 10.3389/fimmu.2025.1431066.


The effect of serum cortisol level on the outcomes of Persistent Inflammation, Immunosuppression and Catabolism Syndrome patients in the intensive care unit.

Eroglu O, Ozgultekin A, Ekinci O Pak J Med Sci. 2025; 41(2):542-547.

PMID: 39926652 PMC: 11803803. DOI: 10.12669/pjms.41.2.10256.


Intravenous immunoglobulin for mortality and inflammatory status in patients with sepsis: a retrospective database study.

Takano H, Kanda N, Wakimoto Y, Ohbe H, Nakamura K Front Immunol. 2025; 15:1511481.

PMID: 39885983 PMC: 11779611. DOI: 10.3389/fimmu.2024.1511481.


References
1.
Eskandari M, Bolgos G, Miller C, Nguyen D, Deforge L, Remick D . Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992; 148(9):2724-30. View

2.
Panopoulos A, Watowich S . Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008; 42(3):277-88. PMC: 2852428. DOI: 10.1016/j.cyto.2008.03.002. View

3.
Boomer J, To K, Chang K, Takasu O, Osborne D, Walton A . Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306(23):2594-605. PMC: 3361243. DOI: 10.1001/jama.2011.1829. View

4.
Brahmamdam P, Inoue S, Unsinger J, Chang K, McDunn J, Hotchkiss R . Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010; 88(2):233-40. PMC: 6607999. DOI: 10.1189/jlb.0110037. View

5.
Van Zee K, Moldawer L, Oldenburg H, Thompson W, Stackpole S, Montegut W . Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol. 1996; 156(6):2221-30. View